intepirdine
Small moleculeexperimental
Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014. — Wikipedia
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
9
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00224497)
Timeline
Indications
Mechanism of action
- Serotonin 6 (5-HT6) receptorANTAGONIST
HTR6 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
O=S(=O)(c1ccccc1)c1cnc2c(N3CCNCC3)cccc2c1- Mol. weight
- 353.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIntepirdine ↗
- ChEMBLCHEMBL1083390 ↗
Also known as
- 3-benzenesulfonyl-8-piperazin-1-ylquinoline
- gsk742457
- gsk742457
- gsk-742457
- intepirdine
- intepirdine
- intepirdine
- rvt-101
- rvt-101
- rvt-101
- sb742457
- sb 742457
- sb-742457
- sb-742457
- sb-742457
- sb-742457
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03924154 | Phase 2 | Jul 1, 2019 | Altavant, PPD |
| NCT02928445 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2016 | Axovant Sciences Inc |
| NCT02910102 | Phase 2 | Oct 1, 2016 | Axovant Sciences Inc |
| NCT02586909 | Phase 3 | Apr 1, 2016 | Axovant Sciences Inc |
| NCT02669433 | Phase 2 | Jan 1, 2016 | Axovant Sciences Inc |
| NCT02585934 | Phase 3 | Oct 1, 2015 | Axovant Sciences Inc |
| NCT00710684 | Phase 2 | Jul 1, 2008 | GlaxoSmithKline |
| NCT00708552 | Phase 2 | Jul 1, 2008 | GlaxoSmithKline |
| NCT00551772 | Phase 1 | Aug 1, 2007 | GlaxoSmithKline |
| NCT00348192 | Phase 2 | May 1, 2006 | GlaxoSmithKline |
| NCT00224497 | Phase 2 | Sep 1, 2005 | GlaxoSmithKline |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Axovant Sciences Inc | For profit | 5 | 5 | 2 | 2015 |
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2005 |
| Altavant | For profit | 1 | 1 | 1 | 2019 |
| PPD | For profit | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1